logo

Last Update

This profile was last updated on 8/21/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong William Oh?

William K. Oh

Professor

Mount Sinai School of Medicine

HQ Phone:  (212) 241-6500

Direct Phone: (212) ***-****direct phone

Email: w***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Mount Sinai School of Medicine

Box 1497 , One Gustave L. Levy Place

New York City, New York,10029

United States

Company Description

Located in Manhattan, Mount Sinai School of Medicine is internationally recognized for ground-breaking clinical and basic-science research, and innovative approaches to medical education. Through the Mount Sinai Graduate School of Biological Sciences, Mount Si...more

Background Information

Employment History

Chief, Division of Hematology and Medical Oncology

Mount Sinai Hospital


Chief Scientific Officer and Chairman of the Science Advisory Board

CheckPoint Sciences Inc


Associate Director for Clinical Research

The Tisch Cancer Institute at The Mount Sinai Medical Center


Assistant Professor of Medicine

Harvard Companies, Inc.


Affiliations

Genitourinary Committee of Cancer and Leukemia Group B

Core Member


Oncology Congress

Advisory Board Member


Prostate Awareness Research Foundation

Scientific Advisory Board Member


American Society of Clinical Oncology

Cancer Education Committee


Education

B.S.

Yale University


M.D.

Dana Farber Cancer Institute


M.D.

Harvard Medical School


M.D.

New York University School of Medicine


MD

The Tisch Cancer Institute


Web References(170 Total References)


Genetic Signatures Offer Clues about Prognosis in Castration-Resistance Prostate Cancer | ProstateCancerVictory.com

prostatecancervictory.com [cached]

In one study, a six-gene panel distinguished between patients with longer and shorter survival rates (PWilliam Oh, MD, of Mount Sinai School of Medicine in New York, and colleagues.
Oh and colleagues used blood samples from 62 men with castration-resistant prostate cancer who were on various treatment regimens at Dana-Farber Cancer Institute in Boston to assess a panel of 168 inflammation-related and prostate cancer-related genes.


Docetaxel Continues to Show Profound Benefits in Prostate Cancer

www.targetedonc.com [cached]

William Oh, MD
Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer, with recent data showing profound benefits with docetaxel in newly diagnosed patients, according to William Oh, MD. According to Oh, these results are particularly interesting because docetaxel has already been available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) for over a decade. He added that there were multiple negative trials involving combining another agent with docetaxel in mCRPC, which preceded the surprising discovery that the addition of the drug early on led to such benefits. In an interview with Targeted Oncology at the 2016 Chemotherapy Foundation Symposium, Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discussed the continued significance of docetaxel in advanced prostate cancer. TARGETED ONCOLOGY: Can you provide an overview of the role of docetaxel in metastatic prostate cancer? Oh: The role of docetaxel in hormone sensitive metastatic prostate cancer is probably one of the biggest new advances in the last 2 years, based on 2 large randomized trials: CHAARTED from the United States and STAMPEDE from the United Kingdom. Oh: This was an interesting result because docetaxel, as everyone knows, has been approved for mCRPC for over a decade, and we have been using it in our practice and it has value in the setting for CRPC. Oh: Tolerability is very, very important because this is an older group of men. Oh: I think the biggest question in the next few years is determining whether using these treatments earlier-the treatments that are approved for mCRPC-will have a more profound impact. Oh: I think this is one of the most profound survival benefits that we have seen in metastatic prostate cancer and that I have seen, basically in my entire career.


www.grandroundsinurology.com

William K. Oh, MD
William K. Oh, MD Icahn School of Medicine at Mount Sinai William K. Oh, M.D. is the Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute. [su_spacer] Dr. Oh's research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, we are assessing changes in the expression of tissue and serum biomarkers due to chemotherapy. Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer. [su_spacer] His major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh's recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score. [su_spacer] Dr. Oh earned a B.S. from Yale University in 1987 and his M.D. from New York University School of Medicine in 1992. He completed an internship and a residency at Brigham and Women's Hospital in Boston and a clinical fellowship at the Dana-Farber Cancer Institute. [su_spacer] From 1997 to 2009, Oh served on the faculty of Harvard Medical School, where he was named Associate Professor of Medicine in 2007. In 2009, he joined The Mount Sinai Medical Center as the Ezra M. Greenspan Professor in Clinical Cancer Therapeutics and Professor of Medicine and Urology, as well as Chief of the Division of Hematology and Medical Oncology in Mount Sinai's Department of Medicine. [su_spacer] Oh is a leading member of the American Society of Clinical Oncology. He has served on multiple editorial boards including the journals The Prostate, Clinical Genitourinary Cancer, the American Journal of Hematology and Oncology and CA - A Cancer Journal for Clinicians. [su_spacer]


www.grandroundsinurology.com

William K. Oh, MD
Dr. William K. Oh spoke at the 21st annual Scottsdale Prostate Cancer Symposium 2016 on Saturday, March 12, 2016 on "Chemotherapy for High Risk Localized Prostate Cancer?". PresentationAbout the AuthorReferencesKeywordsCite View Full Screen in New Window Dr. Oh William K. Oh, M.D. is the Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute. Dr. Oh's research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, we are assessing changes in the expression of tissue and serum biomarkers due to chemotherapy. Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer. His major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh's recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score. Dr. Oh earned a B.S. from Yale University in 1987 and his M.D. from New York University School of Medicine in 1992. He completed an internship and a residency at Brigham and Women's Hospital in Boston and a clinical fellowship at the Dana-Farber Cancer Institute. From 1997 to 2009, Oh served on the faculty of Harvard Medical School, where he was named Associate Professor of Medicine in 2007. In 2009, he joined The Mount Sinai Medical Center as the Ezra M. Greenspan Professor in Clinical Cancer Therapeutics and Professor of Medicine and Urology, as well as Chief of the Division of Hematology and Medical Oncology in Mount Sinai's Department of Medicine. Oh is a leading member of the American Society of Clinical Oncology. He has served on multiple editorial boards including the journals The Prostate, Clinical Genitourinary Cancer, the American Journal of Hematology and Oncology and CA - A Cancer Journal for Clinicians. Oh has been the principal investigator on multiple clinical trials of chemotherapy in castration-resistant (CRPC) prostate cancer and for three trials of neoadjuvant chemotherapy in high-risk localized prostate cancer patients. N/A locally advanced prostate cancer, chemotherapy, neoadjuvant therapy, radical prostatectomy How to cite: Oh, William K. "Chemotherapy for High Risk Localized Prostate Cancer? Grand Rounds in Urology. March 12, 2016. Accessed October 26, 2016. http://www.grandroundsinurology.com/prostate-cancer-william-k-oh-chemotherapy-for-high-risk-localized-prostate-cancer/.


Best and worst of times in dietary supplement news for Chinese herbs

www.supplementquality.com [cached]

Aaron Katz of Columbia-Presbyterian Hospital and William Oh of the Dana-Farber Cancer Institute have reported within the last few weeks on other Chinese herbs and their relation to cancer, but with a markedly different result from the Belgian case reported in the NEJM.
Oh presented his findings to 22,000 cancer specialists from around the world at the May 2000 meeting of the American Society of Clinical Oncology in New Orleans. Subsequent press coverage has been widespread and positive.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory